Articles

  • Aug 8, 2023 | dailysignal.com | Abby Carr

    Must Reads Big TechBorder CrisisChinaCritical Race TheoryElection IntegrityLettersPodcasts  “They call it dope for a reason,” anti-drug campaigns used to say.

  • Aug 7, 2023 | msn.com | Paul Larkin |Abby Carr

    Xylazine—a tranquilizer approved as a sedative for veterinary medical use but not for any use in humans—is currently worsening the opioid crisis. Known on the street as “tranq,” xylazine has become a common additive to substances such as fentanyl, heroin, and cocaine, whether taken orally, by smoking or snorting it, or by injecting it.

  • Aug 6, 2023 | msn.com | Paul Larkin |Abby Carr

    Xylazine—a tranquilizer approved as a sedative for veterinary medical use but not for any use in humans—is currently worsening the opioid crisis. Known on the street as “tranq,” xylazine has become a common additive to substances like fentanyl, heroin, and cocaine, whether taken orally, by smoking or snorting it, or by injecting it.

  • Aug 6, 2023 | 19fortyfive.com | Paul Larkin |Abby Carr

    Xylazine—a tranquilizer approved as a sedative for veterinary medical use but not for any use in humans—is currently worsening the opioid crisis. Known on the street as “tranq,” xylazine has become a common additive to substances like fentanyl, heroin, and cocaine, whether taken orally, by smoking or snorting it, or by injecting it.

  • Aug 4, 2023 | dailysignal.com | Abby Carr

    Must Reads Big Tech Border Crisis China Critical Race Theory Election Integrity Letters Podcasts Xylazine—a tranquilizer approved as a sedative for veterinary medical use but not for any use in humans—is currently worsening the opioid crisis. Known on the street as “tranq,” xylazine has become a common additive to substances like fentanyl, heroin, and cocaine, whether taken orally, by smoking or snorting it, or by injecting it. It creates a double whammy, enhancing the psychotropic effects of...

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →